PolyPeptide Group AG (PPGN.SW) SIX
Currency In CHF
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In CHF
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
1362
First IPO Date
April 28, 2021
| Name | Title | Pay | Year Born |
| Juan Jose Gonzalez | Chief Executive Officer | 1.7M | 1972 |
| Michael Staheli | Head of Investor Relations & Corporate Communications | 0 | 1965 |
| Olivier Ludemann-Hombourger | Director of Global Innovation & Technology | 0 | 1972 |
| Tim Brandl | Interim CFO and Director of Investor Relations, Financial Planning & Analysis | 0 | N/A |
| Christina Del Vecchio | Chief Legal Officer & Corporate Secretary | 0 | 1978 |
| Monika Casanova | Chief Human Resources Officer | 0 | 1979 |
| Rene Vestergaard | Director of Corporate Finance | 0 | N/A |
| Andreas Liese | Corporate Compliance Manager | 0 | N/A |
| Christophe Chevalier | Head of Technical Department - Braine | 0 | N/A |
| Trishul Shah | Interim Director Global Sales & Marketing | 0 | N/A |
PolyPeptide Group AG operates globally as a contract development and manufacturing organization (CDMO), specializing in the production of Good Manufacturing Practice (GMP)-grade peptides. These peptides, available in both proprietary and generic forms, are vital for pharmaceutical and biotechnology companies, serving as key ingredients in approved medicines, compounds undergoing clinical development, and generic drug formulations. The company also produces custom research-grade peptides and actively develops neoantigen peptides to support personalized cancer therapies. Its manufacturing expertise extends to peptides used in commercially approved therapeutics, peptide-based generics for human and veterinary applications, and cosmetic peptides. Additionally, PolyPeptide Group AG provides regulatory affairs support services. Founded in 1952 and headquartered in Zug, Switzerland, the company is a subsidiary of Draupnir Holding B.V.